Revenue
$11.5B
Gross profit
$3.45B
Operating income
−$274M
Free cash flow
$815M
Trailing 12 months · Q3 25 – Q2 26
Overview
About Baxter International
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Leadership
- Andrew P. HiderPresident and Chief Executive Officer
- Joel T. GradeExecutive Vice President and Chief Financial Officer
- Anita A. ZielinskiSenior Vice President, Interim Chief Financial Officer, Chief Accounting Officer & Cntrlr
- Terence John RogersExecutive Vice President and Chief Financial Officer
- Brent ShaferChair of the Board
- James TeaffPresident, CCS
- Julie FosterPresident, Front Line Care
- Steven P. WallacePresident, Adv. Surgery
- Employees
- 37,500
- Business address
- DEERFIELD, IL
- Fiscal year ends
- December 31
- Listed
- NYSE · BAX
Share price
Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$24.22
+$0.36 (+1.51%)past year
- Market cap
- $12.5B
- At close
- Oct 5, 2026
Share price vs index
Baxter International's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Baxter International is ahead, orange while it is behind. The values at the end are each one's change over the range.
Valuation
Market cap divided by trailing 12 months net income (P/E) and revenue (P/S), using the four quarters reported by each day. Turn a series off in the key and the chart rescales to the other.
Revenue mix
Revenue by segment
Q2 26
Revenue reported by each segment. The figure at the top of each column is total revenue. Where a company reports eliminations between segments, the columns show segment revenue before them; hover a column for the eliminations and the reported total. Switch to % to see each segment's share.
Revenue by product
Q1 23
Revenue reported for each product. The figure at the top of each column is the total of the products shown. Switch to % to see each product's share.
Segment growth
Q2 26
Each segment's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.
Product growth
Q2 23
Each product's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.
Revenue by geography
Q2 26
Reported countries and regions in the chosen year or quarter. Known regions use standard geographic footprints. Hover shows the reported region total, never an allocation to individual countries. Ambiguous remainders are not mapped.
Geography growth
Q2 26
Each country's or region's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.
Top geographies
Q2 26
Reported countries and regions in the chosen year or quarter, largest first, in the map's colours. The share of the disclosed geography shows only where the reported parts add up.
Income statement
Revenue, gross profit and net income
Q2 26
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.
Income statement
Q2 26
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalSubtracted
Operating leverage
Q2 26
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.
Cash flow
Operating and free cash flow
Q2 26
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.
Cash flow statement
Q2 26
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted
Capital allocation
Q2 26
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.
Stock-based compensation
Q2 26
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation% of revenue
Balance sheet
Assets, liabilities and equity
Q2 26
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.
Net cash
Q4 25
Cash and short-term investments minus total debt at each quarter end. Below zero, the company owes more than it holds.
Net cashNet debt
War chest
Q2 26
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.